Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer.
Syed N, Coley HM, Sehouli J, Koensgen D, Mustea A, Szlosarek P, McNeish I, Blagden SP, Schmid P, Lovell DP, Hatzimichael E, Crook T.
Syed N, et al. Among authors: crook t.
Cancer Res. 2011 May 1;71(9):3317-27. doi: 10.1158/0008-5472.CAN-10-2048. Epub 2011 Mar 14.
Cancer Res. 2011.
PMID: 21402713
Free article.